Search Results | Blood | American Society of Hematology

1-20 of 51

2 3

Sort by

Sort Order Select

Journal Articles

MYF1001: An Open Label, Dose Escalation and Expansion, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Intermediate 1, Intermediate 2 or High-Risk Myelofibrosis

Terrence Bradley, Andrew Kuykendall, Rami S. Komrokji, Tymara Berry, Souria Dougherty, Laurie Sherman, Lixian Peng, Fei Huang, Ying Wan, Faye Feller, John Mascarenhas

Blood (2022) 140 (Supplement 1): 3941–3942.

DOI: https://doi.org/10.1182/blood-2022-159614

Published: 2022

Journal Articles

Verify: A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera

Srdan Verstovsek, Andrew Kuykendall, Ronald Hoffman, Steffen Koschmieder, Francesco Passamonti, Frank Valone, Nishit B. Modi, Sarita Khanna, Paula G. O'Connor, Suneel K. Gupta, Jean-Jacques Kiladjian

Blood (2022) 140 (Supplement 1): 3929–3931.

DOI: https://doi.org/10.1182/blood-2022-163755

Published: 2022

Journal Articles

Exploratory Predictors for Hydroxyurea Treatment Duration in Polycythemia Vera: A Retrospective Multi-Institutional Database Analysis

Chen Zhang, Douglas Tremblay, John Magnotti, Lukas Ronner, Nikolai A. Podoltsev, Jason Gotlib, Mark L. Heaney, Andrew Kuykendall, Casey L. O'Connell, Angela G Fleischman, Ruben Mesa, Abdulraheem Yacoub, John Mascarenhas, Jamile M. Shammo

Blood (2022) 140 (Supplement 1): 9693–9695.

DOI: https://doi.org/10.1182/blood-2022-157873

Published: 2022

Journal Articles

Synergistic Activity of Luspatercept and Erythroid Stimulating Agents Combination for Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes

Rami S. Komrokji, Luis E. Aguirre, Najla Al Ali, Onyee Chan, Andrew Kuykendall, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, David A. Sallman

Blood (2022) 140 (Supplement 1): 6917–6919.

DOI: https://doi.org/10.1182/blood-2022-169560

Published: 2022

Journal Articles

Assessment of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model in Hypoplastic Myelodysplastic Syndromes

Luis E. Aguirre, Najla Al Ali, Somedeb Ball, Avani M Singh, Akriti G Jain, Onyee Chan, Zaker I. Schwabkey, Sara M Tinsley-Vance, Andrew Kuykendall, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, David A. Sallman, Rami S. Komrokji

Blood (2022) 140 (Supplement 1): 6909–6911.

DOI: https://doi.org/10.1182/blood-2022-171044

Published: 2022

Journal Articles

The Prognostic Impact of FLT3 in NPM1 -Mutated AML: Co-Occurrence of FLT3-ITD and FLT3-TKD Confers Poor Outcomes

Onyee Chan, Najla Al Ali, Somedeb Ball, Justin Grenet, Caroline Hana, Yehuda E. Deutsch, Hammad Tashkandi, Ling Zhang, Mohammad O Hussaini, Seongseok Yun, Andrew Kuykendall, Eric Padron, Gail J. Roboz, Pinkal Desai, Rami S. Komrokji, Kendra Sweet, Jeffrey E. Lancet, David A. Sallman

Blood (2022) 140 (Supplement 1): 3435–3437.

DOI: https://doi.org/10.1182/blood-2022-171197

Published: 2022

Journal Articles

A Product of "Clash of Titans" or True Reflection of Disease Biology? Validation of 2022 WHO and ICC Classifications in a Large Dataset of Patients with Myelodysplastic Syndrome

Somedeb Ball, Avani M Singh, Najla Al Ali, Luis E. Aguirre, Akriti G Jain, Zaker I. Schwabkey, Sara M Tinsley-Vance, Onyee Chan, Andrew Kuykendall, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, David A. Sallman, Rami S. Komrokji

Blood (2022) 140 (Supplement 1): 1118–1120.

DOI: https://doi.org/10.1182/blood-2022-170158

Published: 2022

Journal Articles

Clinical Characterization and Outcomes of Patients with NPM1 -Mutated Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Chen Wang, Onyee Chan, Najla Al Ali, Andrew Kuykendall, Eric Padron, Kendra Sweet, Jeffrey E. Lancet, Rami S. Komrokji, David A. Sallman

Blood (2022) 140 (Supplement 1): 6936–6937.

DOI: https://doi.org/10.1182/blood-2022-160464

Published: 2022

Journal Articles

Luspatercept for Treatment of Lower Risk Myelodysplastic Syndromes: Real World Data Replicates Medalist Study Results and Confirms Activity Among Hypomethylating Agents and Lenalidomide Treated Patients

Rami S. Komrokji, Najla Al Ali, Somedeb Ball, Onyee Chan, Andrew Kuykendall, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, David A. Sallman

Blood (2022) 140 (Supplement 1): 4039–4041.

DOI: https://doi.org/10.1182/blood-2022-169690

Published: 2022

Journal Articles

Characterization of TP53 -Mutated Myelodysplastic Syndromes and Impact of Allelic Status and Concurrent Cytogenetic Abnormalities on Survival Outcomes

Luis E. Aguirre, Najla Al Ali, Akriti G Jain, Onyee Chan, Somedeb Ball, Andrew Kuykendall, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, Rami S. Komrokji, David A. Sallman

Blood (2022) 140 (Supplement 1): 4034–4035.

DOI: https://doi.org/10.1182/blood-2022-171093

Published: 2022

Journal Articles

Improvement in Individual Symptoms and Total Symptom Score (TSS) and Matching-Adjusted Indirect Comparison (MAIC) Analysis to Compare TSS As a Continuous Endpoint in Patients with Myelofibrosis Treated with Pelabresib in Combination with Ruxolitinib Versus Janus Kinase Inhibitor Monotherapy

Ruben Mesa, Marina Kremyanskaya, Andrea Patriarca, Vikas Gupta, Francesca Palandri, Timothy Devos, Claire Harrison, Raajit K. Rampal, Moshe Talpaz, Alessandro Vannucchi, Andrew Kuykendall, Jean-Jacques Kiladjian, Srdan Verstovsek, Gozde Colak, Debarshi Dey, John Mascarenhas

Blood (2022) 140 (Supplement 1): 11056–11059.

DOI: https://doi.org/10.1182/blood-2022-159389

Published: 2022

Journal Articles

Hypoplastic MDS: Validation of the New World Health Organization 2022 Proposal

Zaker I. Schwabkey, Amin Azem, Najla Al Ali, Somedeb Ball, Luis E. Aguirre, Akriti G Jain, Avani M Singh, Sara M Tinsley-Vance, Onyee Chan, Jeffrey E. Lancet, Kendra Sweet, Andrew Kuykendall, Eric Padron, David A. Sallman, Rami S. Komrokji

Blood (2022) 140 (Supplement 1): 6974–6975.

DOI: https://doi.org/10.1182/blood-2022-156974

Published: 2022

Journal Articles

Phase 1/1b Safety Study of Prgn-3006 Ultracar-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

Blood (2022) 140 (Supplement 1): 10313–10315.

DOI: https://doi.org/10.1182/blood-2022-169142

Published: 2022

Journal Articles

Discordance between Patient Goals and Treatment in Older AML Patients

Sara Marie Tinsley-Vance, Cecile A. Lengacher, Andrew Kuykendall, Daniel Lastorino, Amaya Oyola, Onyee Chan, Eric Padron, Areej El-Jawahri, David A. Sallman, Kendra Sweet, Jeffrey E. Lancet, Rami S. Komrokji

Blood (2022) 140 (Supplement 1): 8133–8135.

DOI: https://doi.org/10.1182/blood-2022-163684

Published: 2022

Journal Articles

Secondary AML Mutations Confer Poor Prognosis in Patients with ELN Favorable Risk NPM1 -Mutated AML

Blood (2022) 140 (Supplement 1): 3419–3421.

DOI: https://doi.org/10.1182/blood-2022-165802

Published: 2022

Journal Articles

Validation of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model for Myelodysplastic Syndromes

Blood (2022) 140 (Supplement 1): 1125–1127.

DOI: https://doi.org/10.1182/blood-2022-170878

Published: 2022

Journal Articles

Outcomes of Acute Myeloid Leukemia Relapsed Post-Allogeneic Hematopoietic Stem Cell Transplant Treated with Hypomethylating Agents and Venetoclax Combination: A Single Center Experience

Filip Ionescu, David A. Sallman, Kendra Sweet, Rami S. Komrokji, Onyee Chan, Andrew Kuykendall, Eric Padron, Rawan Faramand, Nelli Bejanyan, Farhad Khimani, Hany Elmariah, Joseph Pidala, Asmita Mishra, Lia Perez, Taiga Nishihori, Jeffrey E. Lancet

Blood (2022) 140 (Supplement 1): 1288–1290.

DOI: https://doi.org/10.1182/blood-2022-165661

Published: 2022

Journal Articles

Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor

Blood (2022) 140 (Supplement 1): 1514–1517.

DOI: https://doi.org/10.1182/blood-2022-162783

Published: 2022

Journal Articles

Clone Size By Conventional Cytogenetics in Myelodysplastic Syndromes Correlates with Clinical Features and Outcomes

Rami S. Komrokji, Najla Al Ali, Virginia Olivia Volpe, Onyee Chan, Andrew Kuykendall, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, David A. Sallman

Blood (2022) 140 (Supplement 1): 9804–9805.

DOI: https://doi.org/10.1182/blood-2022-168439

Published: 2022

Journal Articles

Pelabresib (CPI-0610) As Add-on to Ruxolitinib in Myelofibrosis: Durability of Response and Safety Beyond Week 24 in the Phase 2 MANIFEST Study

Claire Harrison, Marina Kremyanskaya, Prithviraj Bose, Vikas Gupta, Raajit K Rampal, Jonathan Lambert, Moshe Talpaz, Alessandro Vannucchi, Andrew Kuykendall, Jean-Jacques Kiladjian, Srdan Verstovsek, Ruben Mesa, Gozde Colak, Sandra Klein, Soumik Dutta, John Mascarenhas

Blood (2022) 140 (Supplement 1): 9659–9662.

DOI: https://doi.org/10.1182/blood-2022-157735

Published: 2022

2 3

NARROW

MYF1001: An Open Label, Dose Escalation and Expansion, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Intermediate 1, Intermediate 2 or High-Risk Myelofibrosis

Verify: A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera

Exploratory Predictors for Hydroxyurea Treatment Duration in Polycythemia Vera: A Retrospective Multi-Institutional Database Analysis

Synergistic Activity of Luspatercept and Erythroid Stimulating Agents Combination for Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes

Assessment of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model in Hypoplastic Myelodysplastic Syndromes

The Prognostic Impact of FLT3 in NPM1 -Mutated AML: Co-Occurrence of FLT3-ITD and FLT3-TKD Confers Poor Outcomes

A Product of "Clash of Titans" or True Reflection of Disease Biology? Validation of 2022 WHO and ICC Classifications in a Large Dataset of Patients with Myelodysplastic Syndrome

Clinical Characterization and Outcomes of Patients with NPM1 -Mutated Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Luspatercept for Treatment of Lower Risk Myelodysplastic Syndromes: Real World Data Replicates Medalist Study Results and Confirms Activity Among Hypomethylating Agents and Lenalidomide Treated Patients

Characterization of TP53 -Mutated Myelodysplastic Syndromes and Impact of Allelic Status and Concurrent Cytogenetic Abnormalities on Survival Outcomes

Improvement in Individual Symptoms and Total Symptom Score (TSS) and Matching-Adjusted Indirect Comparison (MAIC) Analysis to Compare TSS As a Continuous Endpoint in Patients with Myelofibrosis Treated with Pelabresib in Combination with Ruxolitinib Versus Janus Kinase Inhibitor Monotherapy

Hypoplastic MDS: Validation of the New World Health Organization 2022 Proposal

Phase 1/1b Safety Study of Prgn-3006 Ultracar-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

Discordance between Patient Goals and Treatment in Older AML Patients

Secondary AML Mutations Confer Poor Prognosis in Patients with ELN Favorable Risk NPM1 -Mutated AML

Validation of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model for Myelodysplastic Syndromes

Outcomes of Acute Myeloid Leukemia Relapsed Post-Allogeneic Hematopoietic Stem Cell Transplant Treated with Hypomethylating Agents and Venetoclax Combination: A Single Center Experience

Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor

Clone Size By Conventional Cytogenetics in Myelodysplastic Syndromes Correlates with Clinical Features and Outcomes

Pelabresib (CPI-0610) As Add-on to Ruxolitinib in Myelofibrosis: Durability of Response and Safety Beyond Week 24 in the Phase 2 MANIFEST Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only